Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (19088)	2/25/1999 2:44:00 PM
From: VLAD	Respond to of 23519

DaiS, There is a good point to be made on that post of yours....had Vivus stuck to the research and contracted out the production/sales of muse to a large pharma we now would probably be sitting on a $60.00 stock. We all have a good lesson to learn here: In the future if you see a small biotech stock that has a product that they decide they will manufacture and market on their own BEWARE! We all suffer because of Vivus' decision to bite off way more than they could chew. Leland and Co's problems began from the beginning of January 1997 when they did not have the expertise/resources to ramp up significant production. You already know the marketing/sales nightmare story. I believe we will do OK in the long run but Vivus' mistakes go way beyond a normal "growing pain" problem seen in many small companies.